CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 80K 160K 240K Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 4.8K Q1 '18: 14.4K Q2 '18: 19.2K Q3 '18: 71.6K Q4 '18: 124.4K Q1 '19: 165.6K Q2 '19: 222.4K Q3 '19: 227.5K Q4 '19: 165.5K Q1 '20: 156.8K Q2 '20: 123.1K Q3 '20: 142.6K Q4 '20: 164.5K Q1 '21: 122.4K Q2 '21: 104.5K Q3 '21: 37.5K Q4 '21: 87.8K Q1 '22: 102.8K Q2 '22: 92.8K Q3 '22: 137.8K Q4 '22: 88.6K Q1 '23: 73.6K Q2 '23: 73.6K Q3 '23: 24.6K Q4 '23: 9K Q1 '24: 9K Q2 '24: 17K Q3 '24: 11K Q4 '24: 11K Q1 '25: 14K Q2 '25: 6K Q3 '25: 6K Q4 '25: 6K Q1 '26: 3K Q2 '26: 3K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

-60K 0 60K 120K 180K Q4 '17: -3.2K Q1 '18: 4K Q2 '18: 6.3K Q3 '18: 22.3K Q4 '18: 54K Q1 '19: 83.4K Q2 '19: 123.5K Q3 '19: 157K Q4 '20: 113.9K Q1 '21: 86K Q2 '21: 74.4K Q3 '21: 21K Q4 '21: 39.8K Q1 '22: 48K Q2 '22: 42.5K Q3 '22: 75.5K Q4 '22: 60.1K Q1 '23: 51.9K Q2 '23: 51.9K Q3 '23: 16.5K Q4 '23: 5.4K Q1 '24: 5.4K Q2 '24: 10.2K Q3 '24: 6.6K Q4 '24: 6.6K Q1 '25: 8.4K Q2 '25: 3.6K Q3 '25: 3.6K Q4 '25: 3.8K Q1 '26: 2K Q2 '26: 2K Q2 '18 Q2 '19 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Income TTM

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q3 '16: -576K Q4 '16: -761.5K Q1 '17: -854.5K Q2 '17: -1M Q3 '17: -1.1M Q4 '17: -1.2M Q1 '18: -1.1M Q2 '18: -1.1M Q3 '18: -1M Q4 '18: -1.1M Q1 '19: -1.2M Q2 '19: -1.1M Q3 '19: -1.1M Q4 '19: -1.1M Q1 '20: -1.2M Q2 '20: -1.2M Q3 '20: -1.1M Q4 '20: -1.1M Q1 '21: -1.1M Q2 '21: -1.4M Q3 '21: -2M Q4 '21: -3.1M Q1 '22: -4M Q2 '22: -5.3M Q3 '22: -5.4M Q4 '22: -10.2M Q1 '23: -10.2M Q2 '23: -9.6M Q3 '23: -10.1M Q4 '23: -5.6M Q1 '24: -5.6M Q2 '24: -6.1M Q3 '24: -5.6M Q4 '24: -5.7M Q1 '25: -6.3M Q2 '25: -5.9M Q3 '25: -6.1M Q4 '25: -6.1M Q1 '26: -5.9M Q2 '26: -6.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-45M -30M -15M 0 15M 30M 45M Q3 '16: -580.5K Q4 '16: -766.1K Q1 '17: -861.6K Q2 '17: -1.5M Q3 '17: -1.4M Q4 '17: -2.7M Q1 '18: -10M Q2 '18: -15.5M Q3 '18: -17.1M Q4 '18: -13.7M Q1 '19: -6.9M Q2 '19: -522.3K Q3 '19: -1.4M Q4 '19: -8.5M Q1 '20: -3.9M Q2 '20: -5.7M Q3 '20: -2.9M Q4 '20: -36.3M Q1 '21: -12.2M Q2 '21: -13.3M Q3 '21: -15.5M Q4 '21: 19.2M Q1 '22: -9.8M Q2 '22: -8.7M Q3 '22: -7.8M Q4 '22: -10.1M Q1 '23: -10M Q2 '23: -9.4M Q3 '23: -9.8M Q4 '23: -5.3M Q1 '24: -5.3M Q2 '24: -5.7M Q3 '24: -5.3M Q4 '24: -5.5M Q1 '25: -6.1M Q2 '25: -5.8M Q3 '25: -6M Q4 '25: -6M Q1 '26: -5.8M Q2 '26: -6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 35K 70K 105K Q4 '17: 8K Q1 '18: 10.4K Q2 '18: 12.9K Q3 '18: 49.3K Q4 '18: 70.4K Q1 '19: 82.2K Q2 '19: 98.9K Q3 '19: 70.5K Q4 '19: 45.5K Q1 '20: 45.5K Q2 '20: 37.1K Q3 '20: 46.7K Q4 '20: 50.6K Q1 '21: 36.4K Q2 '21: 30.1K Q3 '21: 16.5K Q4 '21: 47.9K Q1 '22: 54.7K Q2 '22: 50.2K Q3 '22: 62.2K Q4 '22: 28.5K Q1 '23: 21.7K Q2 '23: 21.7K Q3 '23: 8.1K Q4 '23: 3.6K Q1 '24: 3.6K Q2 '24: 6.8K Q3 '24: 4.4K Q4 '24: 4.4K Q1 '25: 5.6K Q2 '25: 2.4K Q3 '25: 2.4K Q4 '25: 2.2K Q1 '26: 994 Q2 '26: 994 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow TTM

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q3 '16: -226.1K Q4 '16: -409.6K Q1 '17: -633.3K Q2 '17: -799.5K Q3 '17: -952.3K Q4 '17: -889.6K Q1 '18: -830.8K Q2 '18: -806.1K Q3 '18: -879.4K Q4 '18: -1.1M Q1 '19: -1.2M Q2 '19: -1.2M Q3 '19: -1.3M Q4 '19: -1.2M Q1 '20: -1.1M Q2 '20: -928.2K Q3 '20: -744K Q4 '20: -434.6K Q1 '21: -680.8K Q2 '21: -780.7K Q3 '21: -997.5K Q4 '21: -2.2M Q1 '22: -3.4M Q2 '22: -4.9M Q3 '22: -5.4M Q4 '22: -7.8M Q1 '23: -10.1M Q2 '23: -9.3M Q3 '23: -9.7M Q4 '23: -8M Q1 '24: -5.1M Q2 '24: -5.6M Q3 '24: -5.2M Q4 '24: -5.3M Q1 '25: -6M Q2 '25: -5.7M Q3 '25: -5.9M Q4 '25: -5.9M Q1 '26: -5.6M Q2 '26: -5.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 600M 1.2B 1.8B Q1 '12: 18.1M Q2 '12: 18.1M Q3 '12: 18.1M Q1 '13: 18.1M Q2 '13: 18.1M Q3 '13: 18.1M Q1 '14: 18.1M Q2 '14: 18.1M Q3 '14: 18.1M Q1 '15: 18.1M Q2 '15: 18.1M Q3 '15: 18.1M Q1 '16: 18.1M Q1 '19: 6.4M Q2 '19: 7.1M Q3 '19: 1.5B Q1 '20: 776.6M Q2 '20: 169.2M Q3 '20: 2.5M Q1 '21: 1.2B Q2 '21: 2.3M Q3 '21: 2.5M Q1 '22: 6.5M Q2 '22: 9M Q3 '22: 14.1M Q1 '24: 1.4M Q2 '24: 1.4M Q3 '24: 1.4M Q1 '25: 2M Q2 '25: 2.6M Q3 '25: 2.6M Q1 '26: 3.7M Q2 '26: 3.7M Q3 '12 Q2 '14 Q1 '16 Q2 '20 Q1 '22 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-75.00 -50.00 -25.00 0.00 25.00 50.00 75.00 Q4 '13: 0.00 Q1 '14: 0.00 Q2 '14: 0.00 Q3 '14: 0.00 Q4 '14: 0.00 Q1 '15: 0.00 Q2 '15: 0.00 Q3 '15: 0.00 Q4 '15: 0.00 Q1 '16: 0.00 Q2 '16: 0.00 Q3 '16: 0.00 Q4 '16: 0.00 Q1 '17: 0.00 Q2 '17: -0.01 Q3 '17: -0.01 Q4 '17: -0.03 Q1 '18: -0.07 Q2 '18: -0.07 Q3 '18: -0.07 Q4 '18: -3.52 Q1 '19: -3.60 Q2 '19: -3.60 Q3 '19: -3.60 Q4 '19: -0.95 Q1 '20: -0.83 Q2 '20: -0.83 Q3 '20: -0.69 Q4 '20: -63.63 Q1 '22: -5.75 Q2 '22: -4.70 Q3 '22: -4.02 Q4 '22: -0.98 Q4 '24: -2.25 Q1 '25: -3.81 Q2 '25: -3.18 Q3 '25: -2.91 Q4 '25: -2.59 Q1 '26: -2.14 Q2 '26: -2.07 Q4 '14 Q1 '16 Q2 '17 Q3 '18 Q4 '19 Q1 '22 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.